IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform

Daisuke Harama1, Takashi Yahata2, Keiko Kagami1, Masako Abe1, Norie Ando1, Shin Kasai1, Minori Tamai1, Koshi Akahane1, Takeshi Inukai1, Nobutaka Kiyokawa2, Abd Aziz Ibrahim4, Kiyoshi Ando4 and Kanji Sugita1

Abstract
The long-term prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is still unsatisfactory even after the emergence of tyrosine kinase inhibitors (TKIs) against chimeric BCR-ABL, and this is associated with the high incidence of genetic alterations of Ikaros family zinc finger 1 (IKZF1), most frequently the hemi-allelic loss of exons 4–7 expressing a dominant-negative isoform Ik6. We found that lenalidomide (LEN), a representative of immunomodulatory drugs (IMiDs), which have been long used for the treatment of multiple myeloma, specifically induced accumulation of Ik6 with the disappearance of functional isoforms within 24 h (i.e., abrupt and complete shut-down of the IKZF1 activity) in Ik6-positive Ph+ ALL cells in a neddylation-dependent manner. The functional IKZF3 isoforms expression was also abruptly and markedly downregulated. The LEN treatment specifically suppressed proliferation of Ik6-positive-Ph+ ALL cells by inducing cell cycle arrest via downregulation of cyclins D3 and E and CDK2, and of importance, markedly upregulated their apoptosis in synergy with the TKI imatinib (IM). Apoptosis of IM-resistant Ph+ ALL cells with T315I mutation of BCR-ABL was also upregulated by LEN in the presence of the newly developed TKI ponatinib. Analyses of flow cytometry, western blot, and oligonucleotide array revealed that apoptosis was caspase-/p53-dependent and associated with upregulation of pro-apoptotic Bax/Bim, enhanced dephosphorylation of BCR-ABL/Akt, and downregulation of oncogenic helicase genes HILLS, CDC6, and MCM5 and 8. Further, the synergism of LEN with IM was clearly documented as a significant prolongation of survival in the xenograft mice model. Because this synergism was further potentiated in vitro by dexamethasone, a key drug for ALL treatment, the strategy of repositioning IMiDs for the treatment of Ik6-positive Ph+ ALL patients certainly shed new light on an outpatient-based treatment option for achieving their long-term durable remission and higher QOL, particularly for those who are not tolerable to intensified therapeutic approaches.

Introduction
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) expressing the chimeric tyrosine kinase BCR-ABL is one of the most common types of ALL in adults.1,2 Although the emergence of tyrosine kinase inhibitor (TKI) imatinib (IM) dramatically improved its short-term prognosis3–5, its long-term prognosis remains unsatisfactory6,7 even after the
development of second and third generations TKIs. Thus, a novel agent that can enhance the activity of TKIs is urgently required.

The Ikaros family zinc finger 1 (IKZF1) is a transcription factor essential for differentiation and proliferation of B-lymphoid progenitor cells. The IKZF1 gene is comprised of 8 exons, and exons 4–6 encode N-terminal zinc fingers required for DNA binding, while exon 8 encodes C-terminal zinc fingers required for homo- and hetero-dimerization (Supplementary Fig. S1A). Although the full-length isoform Ik1 exhibiting the strongest transcriptional activity is most often seen, IKZF1 has many splicing variants having different transcriptional activities. ALLs with poor prognosis are known to have a high ratio of IKZF1 alterations. Among these, the hemi-allelic loss of exons 4–7 expressing the Ik6 isoform which lacks DNA binding but retaining dimerization domains, thus functions as a dominant-negative, are most frequently detected in Ph+ALL patients, reaching 83.7% in adults. The IKZF3 is the secondly identified Ikaros family member and plays an important role in the control of B lymphocyte differentiation and proliferation. The gene structure of IKZF3 and its splicing variants are very similar to those of IKZF1 (Supplementary Fig. S1B). The Aio-1 is the most often seen full-length isoform with the strongest transcriptional activity. In contrast to IKZF1, no genetic IKZF3 alterations have been reported so far in malignancies including leukemia.

Lenalidomide (LEN) and subsequently developed pomalidomide (POM) are derivatives of thalidomide and have been called immunomodulatory drugs (IMiDs). Combined usage of IMiDs with dexamethasone (DEX) has led to significant clinical responses as a dominant-negative, are most frequently detected in Ph+ALL patients, reaching 83.7% in adults. The IKZF3 is the secondly identified Ikaros family member and plays an important role in the control of B lymphocyte differentiation and proliferation. The gene structure of IKZF3 and its splicing variants are very similar to those of IKZF1 (Supplementary Fig. S1B). The Aio-1 is the most often seen full-length isoform with the strongest transcriptional activity. In contrast to IKZF1, no genetic IKZF3 alterations have been reported so far in malignancies including leukemia.

Lenalidomide (LEN) and subsequently developed pomalidomide (POM) are derivatives of thalidomide and have been called immunomodulatory drugs (IMiDs). Combined usage of IMiDs with dexamethasone (DEX) has led to significant clinical responses as a novel agent that can enhance the activity of TKIs is urgently required.

The expression of IKZF1 isoforms was examined in 13 B-cell leukemia cell lines (7 Ph+ and 6 non-Ph) by RT-PCR. As shown in Fig. 1A, all of the Ph+ cell lines expressed the dominant-negative isoform Ik6 mRNA lacking exons 4–7 (Δ4–7). Four cell lines (group A: Ph2, Ph3, Ph4, and Ph7) expressed mRNAs of functional isoforms indicating that Δ4–7 is hemi-allelic, whereas 3 cell lines (group B: Ph1, Ph5, and Ph6) lacked their expression. Because group B type of primary Ph+ALL samples are very rare, complete loss of functional isoforms might be associated with the long-term culture effect. All of the non-Ph cell lines did not express Ik6 mRNA. In western blot analysis (Fig. 1B), group A Ph+ cell lines expressed functional isoforms, but they almost completely disappeared at 24 h after LEN treatment. In contrast, the Ik6 expression showed no change or rather upregulation. Because LEN cannot bind to Ik6 lacking the CRBN binding site (Supplementary Fig. S1), it exclusively binds to functional isoforms, thus leading to their marked ubiquitination. In 6 non-Ph cell lines, the functional isoforms expression was only modestly downregulated after LEN treatment.

**IKZF3 alterations and changes in IKZF3 expression after LEN treatment**

The expression of IKZF3 isoforms was similarly examined by RT-PCR. As shown in Fig. 1C, all of the Ph+ cell lines expressed the full-length isoform Aio-1 mRNA at very high levels with or without low levels of shorter isoform Aio-Δ4 mRNA. In contrast, all of the non-Ph cell lines expressed the Aio-1 mRNA at very low levels. This marked difference appeared to be a hallmark for discriminating Ph+ from non-Ph ALL cell lines. The high levels of Aio-1 mRNA were also documented in LEN-sensitive MM cell lines and T-cell ALL cell lines (Supplementary Fig. S3A). In western blot analysis (Fig. 1D), the Aio-1 expression level was considerably high in 5 Ph+ cell lines (except for Ph5) but it was completely lost after LEN treatment. In contrast, the Aio-1 expression was very low in 6 non-Ph cell lines and showed a very weak downregulation after LEN treatment.

**Analysis of decrease in IKZF3 and 3 expression after LEN treatment**

According to quantification by densitometry (Fig. 1E), the %decrease in the IKZF1 expression was significantly greater in group A Ph+ cell lines. Similarly, the %decrease in Aio-1 expression was significantly greater in Ph+ cell lines. Of interest, marked downregulation after LEN treatment was also documented in LEN-sensitive MM and T-cell ALL cell lines (Supplementary Fig. S3B).

When downregulation process of IKZF3 and 3 after LEN treatment was monitored, Ik1 was started to be downregulated within 1 h and completely disappeared by 6 h, while Aio-1 was started to be downregulated within 3 h and completely disappeared by 24 h (Fig. 1F). This LEN effect was completely canceled by preincubation with NEDD8-activating enzyme inhibitor MLN4924 (Fig. 1G), indicating that loss of IKZF3 and 3 expression is initiated by the LEN-induced neddylation of CRL4CRBN.
Effect of LEN on thymidine uptakes

Ph+ (n = 6) and non-Ph (n = 12) cell lines were cultured in the presence or absence of LEN for 72 h, and thymidine uptake assays were performed. As shown in Fig. 2A, although there was no difference in the % inhibition between Ph+ and non-Ph cell lines, the %
The synergistic effect of LEN with IM

It should be very interesting to examine whether LEN could enhance the activity of imatinib (IM). In both thymidine uptakes and alamarBlue cytotoxicity assays (Fig. 3A and B), LEN significantly enhanced the effect of IM, and the IC50 of IM was thus shifted from 1.05 to 0.088 µM in the presence of LEN (Fig. 3C). To determine whether the effect of LEN and IM is synergistic or additive, KOPN57bi cells were cultured for 72 h in the presence of 3 concentrations of IM and/or 6 concentrations of LEN and the combination index (CI) was calculated by alamarBlue cytotoxic assays. As shown in Fig. 3D, CI was always <0.8 showing strong synergy at any concentrations of LEN and IM.

In flow cytometric analysis using the PI staining, the subdiploid apoptotic population was markedly upregulated by IM in the presence of LEN (Fig. 3E). This induction of apoptosis was suppressed by pretreatment with pan-caspase inhibitor Z-VAD-FMK (Fig. 3F). Flow cytometric analysis using the Annexin-V/PI double staining clearly revealed the marked increase in the late apoptotic population by LEN and IM (Fig. 3G). This apoptosis induction was accompanied with an increase in the cleaved caspase-3-positive population (Fig. 3H). The LEN effect was similarly observed in other group A but only modestly in group B Ph+ cell lines (Supplementary Fig. S4).

Marked inhibitory effect of LEN in colony formation assays

It is very important to see the effect on repopulating potential of leukemia cells for evaluating anti-leukemia agents. The colony formation assay was thus performed in the presence or absence of LEN and/or IM. Of surprise, colony formation was markedly suppressed up to 12.7% of the control by LEN alone, and was further suppressed up to 4.2% by cotreatment of LEN and IM (Fig. 3I), indicating that LEN synergizes with IM to profoundly suppress the repopulating potential of Ik6 positive Ph+ ALL cells.

Effect of LEN on cell cycle progression

To pursue the mechanism of the LEN-induced inhibition of thymidine uptakes, KOPN57bi cells were cultured in the presence or absence of LEN for 72 h, and cell cycle analysis was performed (Fig. 2C). As representatively shown in the left panel, the S phase was decreased with a modest increase in the subdiploid apoptotic population. The G0/G1 phase was modestly increased, while the G2/M phase was modestly decreased. In four repeated experiments, a significant decrease in the phases of S and G2/M with a small increase in the subdiploid region were documented after LEN treatment (right panel).

Cell cycle progression is primarily regulated by activities of cyclin-dependent kinases (CDKs) which are upregulated by cyclins and downregulated by CDK inhibitors18. Western blot analysis showed downregulation of cyclins D3 and E potentiating the G1 to S phase transition and CDK2 implicating the M phase progression after LEN treatment (Fig. 2D).

Synergistic effect of LEN with IM

It is very important to see the effect on repopulating potential of leukemia cells for evaluating anti-leukemia agents. The colony formation assay was thus performed in the presence or absence of LEN and/or IM. Of surprise, colony formation was markedly suppressed up to 12.7% of the control by LEN alone, and was further suppressed up to 4.2% by cotreatment of LEN and IM (Fig. 3I), indicating that LEN synergizes with IM to profoundly suppress the repopulating potential of Ik6 positive Ph+ ALL cells.

Inhibition in group A Ph+ cell lines (n = 4) was significantly greater than that in non-Ph cell lines (n = 12), suggesting that complete abrogation of IKZF1 activity should contribute to the LEN-induced inhibition of thymidine uptakes. This significant % inhibition was observed starting from day 3 and thereafter (Fig. 2B).
Effect of other combinations of IMiDs and TKIs for inducing apoptosis

The effect of newly developed IMiD pomalidomide (POM) was evaluated. While the synergistic apoptosis-inducing effect of POM (2.5 μM) was almost identical to that of LEN by flow cytometric analysis (Fig. 4A), this was more strongly demonstrated in alamarBlue cytotoxic assays (Fig. 4B). The effect of the second-generation TKI dasatinib (DA) was next evaluated. Although DA alone showed almost no cytotoxic effect at 100 nM, cotreatment of LEN with DA markedly enhanced cytotoxicity (Fig. 4C).
Ponatinib (PO) is a potent kinase inhibitor called the third-generation TKI capable of suppressing the leukemia clones harboring the T315I mutation of BCR-ABL. In analysis using the IM-resistant SU/SR cell line with T315I mutation (expressing lk6 only), the PO effect was markedly potentiated in the presence LEN (Fig. 4D).
Western blot analysis of expression of apoptosis- and signal transduction-related molecules after LEN and IM treatment

As shown in Fig. 5, the expression of anti-apoptotic Bcl-2 and Bcl-xL was rather upregulated (A), but the expression of pro-apoptotic Bax, particularly its cleaved active form p18, was markedly upregulated after LEN and IM treatment (B). Because cathepsin promotes degrada-
tion of p18 and calpain promotes cleavage to p18, the effect of cathepsin or calpain inhibitor was examined, but either inhibitor showed no considerable effects on induction of apoptosis (Supplementary Fig. S5A, S5B), suggesting that the total increase in both forms of Bax might be important for inducing apoptosis after LEN and IM treatment. Supportively, Bax channel inhibitor partially but significantly restored the viable population (Supplementary Fig. S5C). The expression of proapoptotic BH3-only molecule Bim was upregulated, but the c-Myc expression showed no change (C) in contrast to its marked decrease in multiple myeloma21. Changes in activating status of signal-transducing molecules were next addressed. Although LEN treatment alone did not alter phosphorylating status of BCR-ABL, STAT5, Akt, and Erk1/2, LEN treatment significantly enhanced IM-induced dephosphorylation of BCR-ABL and Akt (D), indicating that LEN renders Ph+ALL cells low activation status in synergy with IM, which might be associated with high susceptibility to apoptosis.

Array analysis of a panel of genes expression after LEN and IM treatment

To comprehensively understand the mechanism of inducing apoptosis after LEN and IM treatment, array analysis of a panel of genes was performed. From the genes which exhibited the expression two times higher in the LEN and IM treatment than in either LEN or IM alone treatment, markedly upregulated 3 genes MDM2 (murine double minute 2), BTG2 (B-cell translocation gene 2), and IKZF3 were selected and changes in their mRNA levels were presented in Fig. 6A. The MDM2 gene encodes E3 ubiquitin ligase which downregulates apoptotic p53 activity, and the BTG2 gene encodes a transcriptional cofactor which was isolated as the sequence induced by p53. The IKZF3 gene encodes IKZF3 which binds the Bcl-2 promoter and upregulates Bcl-2 expression having a strong anti-apoptotic function. Collectively, it assumes that the upregulation of these 3 genes is not a causative event involving initiation of apoptosis but rather an antagonizing event reflecting cellular responses against p53-dependent apoptosis.

On the other hand, markedly downregulated 4 genes HELLS (lymphoid-specific helicase), CDC6 (cell division control protein 6), MCM4 (mini-chromosome maintenance 4), and MCM8, all encoding proteins with a helicase activity, were selected and their changes in their mRNA levels were presented in Fig. 6B. The HELLS gene encodes a chromatin remodeler, which is expressed in
tumor tissues and its overexpression is associated with poor prognosis\textsuperscript{22,23}. The \textit{CDC6} gene encodes DNA replication licensing factor\textsuperscript{24} required for loading MCMs \textit{2–7} helicases onto DNA\textsuperscript{23}, while MCM8 helicase specifically forms a complex with MCM9 which is required for DNA resection at double-strand breaks\textsuperscript{25}. Considering that HELLS, CDC6, and MCM proteins are all expressed in most cancers and their overexpression is associated with poor survival by functioning as oncogenes\textsuperscript{26,27}, it assumes that downregulation of these 4 helicase genes might be, at least in part, involved in the inducing apoptosis of leukemia cells after LEN plus IM treatment.

\textbf{Engraftment and survival rate of xenografted NOG mice}

To pursue the in vivo effect of LEN and IM, xenograft studies using NOG mice were performed. The mice transplanted with KOPN57bi cells were divided into 4 groups receiving saline, IM alone, LEN alone, and LEN and IM for 3 weeks, and observed over 60 days. As shown in Fig. 7A, the engraftment rate was significantly lower in the IM alone or LEN alone group than in the saline group, and it was further decreased in the LEN and IM group. Of most importance, although median survival days of saline, IM alone, and LEN alone groups showed no significant differences between 2 of the 3 groups, the median survival days in the LEN and IM group was prolonged to 52.5 days, which was significantly longer than that in the other 3 groups (Fig. 7B). These results clearly showed that the combined administration of LEN and IM elongated the survival by approximately 180% longer when compared with the control group.

\textbf{Additive effect of dexamethasone}

In the treatment of MM, LEN has shown to be more effective when used together with DEX\textsuperscript{14}. In the treatment of ALL, DEX has been used for decades as one of key drugs. In the treatment of Ph+ ALL, the combination consisting of DEX and TKI has been widely used as the induction therapy\textsuperscript{28}, because the addition of DEX enhances the sensitivity of leukemia cells to TKI and vice versa. It is therefore interesting to see the additive effect of
DEX on the LEN and IM combination. For this purpose, KOPN57bi cells were cultured for 48 h in the presence or absence of LEN and IM with or without the addition of 2.5 nM DEX. As shown in Fig. 8A, the viable population in flow cytometric analysis was as low as 17.0% after 3 drugs combination (LEN + IM + DEX +), which was clearly more effective when compared with 2 types of 2 drugs combination (LEN + IM + or IM + DEX +) (Fig. 8B), and was also observed in the alamarBlue cytotoxic assays (Fig. 8C). This DEX effect was observed at a concentration as low as 1.25 nM and in a dose-dependent manner (Fig. 8D). The effect of 3 drugs combination was similarly observed when POM was used instead of LEN (Fig. 8E).

Of clinical importance, the viability of IM-resistant SU/SR cells harboring the T315I mutation of BCR-ABL was strikingly decreased up to 4.8 ± 2.7% by the LEN + PO + DEX + combination (Fig. 8F).

**Discussion**

Because IKZF1 is known to function as a transcriptional regressor of glucose and energy supply in synergy with other B-lymphoid transcription factors leading to the enforcement of a state of chronic energy deprivation, downregulation of IKZF1 activity generally leads to enhanced malignant characteristics requiring a higher energy state for proliferation and invasion in ALL cells. Downregulation of IKZF1 activity also leads to the decreased expression of the NR3C1 gene encoding the glucocorticoid receptor (GR), whose expression levels primarily determine the GR sensitivity to ALL cells. Thus, downregulation of IKZF1 activity by genetic alterations frequently found in Ph+ALL cases is definitely associated with their malignant nature and poor prognosis.

In the present study, we showed that abruptly evoked complete shut-down of the IKZF1 activity should be a key factor in the suppression of cell viability and proliferation in ALL cells.
for enhancing apoptosis of Ik6-positive Ph+ALL cells in synergy with the effective TKI. Here, it should be noted that transcription factors exhibit different and sometimes opposite effects on cells depending on their expression levels. For example, whereas GATA2-null mice and GATA2-conditionally knock-out mice show no development of hematological neoplasms, GATA2-mutant mice in which GATA2 activity is reduced to 20% of the wild-type mice show a predisposition to the development of myelomonocytic leukemia. The similar observation has also been documented in other transcription factors such as PU.1. Thus, there will be a critical shift of vulnerability to additional apoptosis-inducing stimuli from low sensitivity in the pretreated cells to very high sensitivity in the cells just after LEN treatment where compensation mechanism(s) for proliferation and survival by other transcription factors will not work in time. The marked downregulation of IKZF3 activity from distinctly high levels toward zero should be additionally implicated for induction of apoptosis in synergy with TKIs. Of interest, the high IKZF3 expression and its marked downregulation after LEN treatment was similarly

![Array analysis of changes after LEN and IM treatment](image)

**Fig. 6 Array analysis of changes after LEN and IM treatment.** KOPN57bi cells were cultured for 24 h in the presence or absence of LEN (5 μM) or IM (0.5 μM) alone or both, and harvested. The isolated RNAs were reverse-transcribed and labeled using the GeneChip HT 3′ N7 Expression kit (Affymetrix, Santa Clara, CA) as instructed by the manufacturer. The labeled probes were hybridized in triplicate to GeneChip Human Genome-U133 Plus 2.0 Arrays (Affymetrix) as described previously. The arrays were analyzed using GeneChip Operating Software 1.2 (Affymetrix) and GeneSpring GX 14.9 software (Agilent Technologies, Santa Clara, CA). Genes with a p value lower than 0.01 by one-way ANOVA were selected. After performing fold-change analysis, genes that exhibited two times higher or lower expression were selected in each of the culture conditions. By using selected gene lists, single experiment pathway analysis was performed. A Upregulated genes. Among upregulated genes showing 2-fold higher by LEN plus IM treatment than LEN alone treatment, fold changes in RNAs of 3 genes MDM2, BTG2, and IKZF3 were presented in each culture condition. B Downregulated genes. Among downregulated genes showing 2-fold lower by LEN plus IM treatment than by LEN or IM alone treatment, fold changes in RNAs of 4 genes HELLS, CDC6, MCM4, and MCM8 were presented in each culture condition.
observed in LEN-sensitive MM and T-cell type malignancies. We also showed that this induction of apoptosis was caspase- and p53-dependent and mediated by upregulation of the apoptosis-inducing Bax/Bim expression and the downregulated phosphorylation of BCR-ABL/Akt, where it was shown by the array analysis that downregulated expression of several oncogenic helicase genes are implicated. From a clinical point of view, it is important that the cytocidal effect of LEN is achieved at a concentration of 5 μM in our experiments. Although this concentration of LEN is modestly higher than the serum concentration of Cmax when 25 or 35 mg of LEN is first administered to the patients, a wide range of LEN concentrations is effective in terms of synergy with TKIs as demonstrated in Fig. 3D. It is noteworthy to see the recent report describing a Ph+ ALL patient who relapsed after conventional chemotherapy and IM but achieved durable remission by oral treatment with LEN plus nilotinib, the second generation TKI.

Occupancy of Ph+ type increases along with a higher age in ALL patients. In fact, Ph+ type is >50% of ALL in patients older than 60 years. However, in the majority of protocol studies for Ph+ALL being carried out in American and European countries including Japan, the eligibility criteria for being enrolled in the study is restricted to the patients younger than 60–65 years with good performance status, adequate organ function, and no active infection, because older patients particularly those with organ dysfunction cannot tolerate to and have an increased risk of severe adverse effects to the protocol consisting of multi-drug intensified chemotherapy possibly followed by allogeneic hematopoietic transplantation. If an effective treatment regimen by use of IMiD on an out-patient basis can be established, this therapy could certainly facilitate long-term and high QOL survival of Ph+ALL patients, particularly those who cannot afford to receive multidisciplinary intensified therapeutic approaches.

Materials and methods

Reagents and antibodies

Detailed information of reagents and antibodies was presented in Supplementary methods.

Leukemia cell lines

Eight TKI-sensitive or -resistant Ph+ and 6 non-Ph B-cell leukemia lines were used, which have been described previously.

Reverse transcription-polymerase chain reaction (RT-PCR)

RT-PCR analyses were performed as described previously.

Western blot analysis

The membranes were incubated with various primary antibodies and stained with the peroxidase-conjugated
Fig. 8 Effect of DEX for inducing apoptosis of KOPN57bi cells. A Flow cytometric analysis of DEX effect on LEN plus IM-induced apoptosis. KOPN57bi cells were cultured for 48 h in the presence or absence of LEN (5 μM) plus IM (0.5 μM) with or without the addition of 2.5 nM DEX (SIGMA-Aldrich), and flow cytometric analysis was performed after Annexin-V/PI staining. B Comparative analysis of apoptosis-inducing effects between 2-drugs and 3-drugs. KOPN57bi cells were cultured for 48 h in the presence or absence of LEN (5 μM) plus IM (0.5 μM), IM plus DEX (2.5 nM), or LEN plus IM plus DEX, and flow cytometric analysis was performed after Annexin-V/PI staining. The X and Y axes shown in A and B indicate log fluorescence intensities of Annexin-V and PI, respectively. C Effect of DEX on LEN plus IM-induced cytotoxicity. KOPN57bi cells were cultured for 48 h in the presence or absence of LEN (5 μM) plus IM (0.5 μM) with or without the addition of DEX (2.5 nM) and alamarBlue cytotoxic assays were performed. D Dose-dependent effect of DEX on LEN plus IM-induced cytotoxicity. KOPN57bi cells were cultured for 48 h in the presence or absence of LEN (5 μM) plus IM (0.5 μM) with different concentrations (0, 1.25, 2.5, and 5 nM) of DEX, and alamarBlue cytotoxic assays were performed. E Comparative analysis of LEN and POM in 2-drugs and 3-drugs-induced cytotoxicity. KOPN57bi cells were cultured for 48 h in the presence or absence of LEN (5 μM), POM (2.5 μM), or IM (0.5 μM) with or without the addition of DEX (2.5 nM), and alamarBlue cytotoxic assays were performed. F Synergistic effect of LEN, PO, and DEX on cytotoxicity in SU/SR cells harboring T315 I mutation. The Ph+ SUV cells with T315I mutation were cultured for 48 h in the presence or absence of PO (5 nM) alone or LEN (5 μM) plus PO with or without the addition of DEX (2.5 nM), and alamarBlue cytotoxic assays were performed.
second antibody. The bands were visualized using chemiluminescence detection reagents as described previously.\(^{18}\)

**Thymidine uptake assays**

\(^{3}H\)-thymidine uptake assays were performed as described previously.\(^{24}\) Percentage inhibition was calculated as follows: \(([(\text{cpm of treated})/(\text{cpm of untreated})] − 1) \times 100\).

**alamarBlue cytotoxic assays**

Cytotoxic assays were performed as described previously.\(^{43}\)

**Determination of combination index (CI)**

Leukemia cells were cultured for 48 h with 3 concentrations of IM in the presence or absence of 6 concentrations of LEN, and cytotoxic assays were performed to determine CI as described previously.\(^{47}\)

**Flow cytometric analysis**

Flow cytometric analysis was performed as described previously.\(^{44}\)

** Colony formation assays**

Leukemia cells were suspended in a semi-solid α-MEM medium and incubated for 14 days as described previously.\(^{48}\)

**Generation of xenografted mice and in vivo drug treatment studies**

Leukemia cells were intravenously infused into NOG mice and were classified into 4 groups receiving saline, LEN alone, IM alone, and LEN plus IM.

**Oligonucleotide array experiments and data analysis**

Leukemia cells were cultured for 24 h in the presence or absence of either LEN or IM alone or both. The arrays were analyzed as described previously.\(^{49}\) The data have been deposited to the Gene Expression Omnibus database repository with the dataset identifier GSE155597.

**Statistics**

Unpaired \(t\), Mann–Whitney \(U\), one-way ANOVA, and log-rank tests were used for analyzing the data in thymidine uptakes, cytotoxicity and flow cytometry, the comparison between two groups, array analysis, and the xenograft mice studies, respectively. A \(p\)-value of <0.05 was considered significant.

**Author details**

1Department of Pediatrics, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
2Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
3Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
4Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan

**Author contributions**

D.H. conceived and designed the experiments, curated and analyzed data, and wrote the original draft. Y.T. curated and analyzed data of in vivo experiments and wrote the manuscript. A.A.I. and K.A. curated and analyzed data of in vivo experiments. K.K., M.A., N.A., S.K., M.T., K.A., and T.I. curated and analyzed data. N.K. performed oligonucleotide array experiments and wrote the manuscript. K.S. conceptualized the experiments, reviewed and edited the manuscript, revised it critically for important intellectual content, and gave final approval for this study.

**Funding**

This work was supported by JSPS KAKENHI Grant Number JP16K19635.

**Conflict of interest**

The authors declare no competing interests.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Supplementary information**

The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00523-y.

Received: 2 April 2021 Accepted: 1 May 2021
Published online: 11 June 2021

**References**

1. Luglio, T. G., Pendergast, A. M., Muller, A. J. & Witte, O. N. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 247, 1079–1082 (2000).
2. Geissner, B. et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99, 1536–1543 (2002).
3. Kantarjian, H. M. et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. 18, 547–561 (2000).
4. Yanada, M. et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant. 36, 867–872 (2005).
5. Lim, S. N. et al. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am. J. Hematol. 90, 1013–1020 (2015).
6. Daver, N. et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100, 653–661 (2015).
7. Aricò, M. et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J. Clin. Oncol. 28, 4755–4761 (2010).
8. Wang, J. H. et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537–549 (1996).
9. Georgopoulos, K. et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79, 143–156 (1994).
10. Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008).
11. Morgan, B. et al. Alokos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J. 16, 2004–2013 (1997).
12. Kuppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 5, 251–262 (2005).
13. Finn, E. C. & Ebert, B. L. The novel mechanism of lenalidomide activity. Blood 126, 2366–2369 (2015).
14. Weber, D. M. et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133–2142 (2007).
22. Robinson, M. H. et al. Upregulation of the chromatin remodeler HELLS is associated with glioma stem cells.

23. Zhang, G. et al. Chromatin remodeler HELLS maintains glioma stem cells.

24. Specian, C., Chen, Z., Li, H. & Stillman, B. ATPase-dependent cooperative binding of ORC and Cdc6 to origin DNA.

26. Isaac, M. S. M., Yousef, E., Tahir, M. R. & Gaboury, L. A. MCM2, MCM4, and MCM6 in breast cancer: clinical utility in diagnosis and prognosis.

29. Chan, L. N. et al. Metabolic gatekeeper function of B-lymphoid transcription factor ATM in Philadelphia chromosome-positive acute lymphoblastic leukemia.

32. Harada, N., Hasegawa, A., Hirano, I., Yamamoto, M. & Shimizu, R. GATA2 erythroid progenitors result in uropathies resembling human CAKUT.

33. Will, B. et al. Minimal PU1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.

34. Ogura, M. et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATL-001): a phase 1, multicentre, dose-escalation study.

35. Lai, B. et al. Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: a case report.

36. Fielding, A. K. et al. UKALLXV/EOCOG993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

37. Bassan, R. et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

38. Ribera, J. M. et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.

39. Tanguy-Schmidt, A. et al. Long-term follow-up of the imatinib GGRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.

40. Yarada, M. et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.

41. Hirose, K. et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(1;17)(q11.2;q21).

42. Uno, K. et al. TFIIB-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.

43. Huang, M. et al. Clofarabine exerts anti-leukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.

44. Nakamura, M. et al. Notch1 activation enhances proliferation via activation of cdk2 and delays differentiation of myeloid progenitors.

45. Tokunaga, K. et al. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.

46. Caballero, R. et al. Combinatorial effects of splice variants modulate function of Aiolos.

47. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships, the combined effects of multiple drugs or enzyme inhibitors.

48. Ilijima, K. et al. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome.

49. Miyagawa, Y. et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing’s family tumor-like phenotypes to human mesenchymal progenitor cells.

50. Euvir's family tumor-like phenotypes to human mesenchymal progenitor cells.